Have you registered for #ASGCT2025? Secure your spot to join us in New Orleans or virtually at the for the premier event in gene and cell therapy.
The Gene, Cell, & RNA Therapy Landscape report, created in partnership with Citeline, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
In Q4 2024:
Approvals across three modalities: Aucatzyl for acute lymphocytic leukemia, RegeneCyte for blood disorders, and Tryngolza for lipoprotein lipase deficiency
Seed and Series A financing reached $609.2 million, up 26% from Q3
Cell therapy trials are expanding beyond cancer, with 58% now focused on non-oncology applications
Read the Full Report
Read all available reports from 2024.
Read all the landscape reports from 2023.
Read all the landscape reports from 2022.
Read all the reports from 2021 here.
May 13-17, 2025 | New Orleans
© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico